PT  - JOURNAL ARTICLE
AU  - Jason M Tarkin
AU  - Juan Carlos Kaski
TI  - Pharmacological treatment of chronic stable angina pectoris
AID  - 10.7861/clinmedicine.13-1-63
DP  - 2013 Feb 01
TA  - Clinical Medicine
PG  - 63--70
VI  - 13
IP  - 1
4099  - http://www.rcpjournals.org/content/13/1/63.short
4100  - http://www.rcpjournals.org/content/13/1/63.full
SO  - Clin Med2013 Feb 01; 13
AB  - Chronic stable angina is the most common manifestation of ischaemic heart disease in the developed world and is associated with impaired quality of life and increased mortality. The pathogenesis of stable angina is complex and often, albeit not always, involves flow-limiting epicardial coronary artery stenoses (atheromatous plaques) that reduce the ability of the coronary circulation to deliver appropriate blood supply to the myocardium. The coronary microcirculation can also play an important role. An imbalance between myocardial oxygen supply and metabolic oxygen demand causes the symptoms of angina pectoris and represents a major therapeutic target. Rational treatment requires a multi-faceted approach combining lifestyle changes, aggressive management of modifiable coronary artery disease risk factors, pharmacological therapy and myocardial revascularisation when appropriate. Despite modern therapies, many patients continue to suffer from angina. Several new anti-anginal drugs have been introduced that might allow more effective symptom control. These novel agents have specific mechanisms of action and fewer side effects compared to conventional drugs. The combined use of traditional and novel treatments is likely to increase the proportion of patients who are managed successfully with medical therapy alone. This article briefly reviews recent advances in the pharmacological management of chronic stable angina pectoris, highlighting how an understanding of the prevailing pathogenic mechanisms in the individual patient can aid appropriate selection of therapeutic strategies and improve clinical outcome.